Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026)
Stoke Therapeutics' (STOK) quarterly Other Non Operating Income came in at $18000.0 in Q1 2026, down 35.71% year-on-year from $28000.0 in Q1 2025, and up 116.36% quarter-over-quarter from -$110000.0 in Q4 2025.
Stoke Therapeutics (STOK) Other Non Operating Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Other Non Operating Income history runs 8 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- On a quarterly basis, Other Non Operating Income fell 35.71% year-over-year to $18000.0 in Q1 2026; TTM through Mar 2026 was -$61000.0, a 129.19% decrease from a year earlier, with the FY2025 full-year figure at -$51000.0, up 79.35% from the prior year.
- Other Non Operating Income advanced to $18000.0 in Q1 2026 per STOK's latest filing, from -$110000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $201000.0 in Q4 2024 and bottomed at -$428000.0 in Q1 2024.
- The 5-year median for Other Non Operating Income is $41000.0 (2023), against an average of $3117.6.
- Biggest YoY gain for Other Non Operating Income was 390.24% in 2024; the steepest drop was 1119.05% in 2024.
- Year by year, Other Non Operating Income stood at $42000.0 in 2022, then fell by 2.38% to $41000.0 in 2023, then jumped by 390.24% to $201000.0 in 2024, then plunged by 154.73% to -$110000.0 in 2025, then surged by 116.36% to $18000.0 in 2026.
- Per Business Quant, the three latest STOK Other Non Operating Income figures stand at $18000.0 (Q1 2026), -$110000.0 (Q4 2025), and $3000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -110,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | -428,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | 42,000.00 |
| Mar 31, 2022 | 42,000.00 |
| Dec 31, 2021 | 42,000.00 |
| Sep 30, 2021 | 42,000.00 |
| Jun 30, 2021 | 28,000.00 |